Welcome to our dedicated page for Amgen SEC filings (Ticker: AMGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
Amgen Inc. senior vice president of business development Rachna Khosla reported a tax-related share disposition on company stock. On March 16, 2026, 707 shares of Amgen common stock were withheld at a price of $366.21 per share to satisfy tax obligations, rather than sold in the open market.
After this tax-withholding disposition, Khosla directly holds 8,291 Amgen shares. This amount includes 120 Dividend Equivalents granted under Amgen’s 2009 equity incentive plan, which convert into common stock on a one-to-one basis as related restricted stock units vest.
Amgen Inc. senior vice president and chief compliance officer Nancy A. Grygiel reported a routine tax-related share withholding. On March 16, 2026, 787 shares of Amgen common stock were disposed of at $366.21 per share to satisfy tax obligations tied to equity compensation.
After this tax-withholding disposition, she directly holds 8,488 Amgen shares, which include 122 dividend equivalents that will pay out in shares as they vest. She also indirectly holds 106.1873 shares through the company’s 401(k) plan stock fund.
Amgen Inc. EVP & CFO Peter H. Griffith reported a Form 4 transaction showing a tax-related share disposition. On March 16, 2026, 5,748 shares of Amgen common stock were disposed of at $366.21 per share to satisfy tax obligations by delivering shares. After this withholding transaction, he directly holds 49,001 shares of common stock. His holdings include 756 Dividend Equivalents granted under Amgen’s equity incentive plan, which are paid out in shares on a one-for-one basis as related restricted stock units vest.
Amgen Inc. executive Jonathan P. Graham reported a routine tax-related share disposition. On this Form 4, 5,353 shares of Amgen common stock were withheld at $366.21 per share to satisfy tax obligations, rather than sold in the open market. After this withholding, he directly owns 39,267 shares. The reported holdings include 659 dividend equivalent units that will pay out in Amgen shares as related restricted stock units vest.
Amgen Inc. executive Murdo Gordon reported a routine tax-related share disposition. On March 16, 2026, the EVP, Global Commercial Operations delivered 6,691 shares of Amgen common stock at $366.21 per share to cover tax obligations, rather than selling them on the open market.
Following this tax-withholding disposition, Gordon directly holds 50,292 Amgen shares. His holdings also include 825 dividend equivalent units tied to unvested restricted stock units, which will be paid out in Amgen common stock as those awards vest.
Amgen Inc.’s Chairman, CEO and President Robert A. Bradway reported a tax-related share disposition. On March 16, 2026, 21,294 shares of Amgen common stock were withheld at $366.21 per share to cover tax obligations, a non-market transaction classified as a tax-withholding disposition. Following this, Bradway directly holds 501,862 shares of common stock. He also reports indirect holdings of 60,060 shares by a GRAT, 60,060 shares by a spousal GRAT, and 29,940 shares by his spouse. The direct holdings include 2,696 dividend equivalents that will settle in shares as related restricted stock units vest.
Amgen Inc. vice president, finance and chief accounting officer Matthew C. Busch reported a small tax-related share disposition. On the reported date, 327 shares of Amgen common stock were withheld at a price of $366.21 per share to satisfy tax obligations, classified as a tax-withholding disposition rather than an open-market sale.
After this transaction, Busch directly held 4,048 shares of Amgen common stock. His holdings include 68 dividend equivalents credited under Amgen’s equity incentive plan, which will be paid out in common shares as related restricted stock units vest.
Amgen Inc. Chairman, CEO and President Robert A. Bradway reported several equity transactions in the company’s stock. He exercised stock options, receiving 119,782 shares of common stock at $156.35 per share through a derivative exercise.
To cover the option exercise price and related tax withholding, 84,285 shares of common stock were withheld by the company and disposed of under a tax-withholding arrangement. After these transactions, Bradway directly owned 492,643 shares of Amgen common stock, and also had indirect ownership of 90,000 shares held through a GRAT and a spousal GRAT.
The directly owned shares include 2,414 dividend equivalents tied to unvested restricted stock units, which will be paid in Amgen common stock on a one-to-one basis as those units vest.
Santos Esteban reported acquisition or exercise transactions in this Form 4 filing.
Amgen executive Esteban Santos reported an equity award of 11,259 shares of common stock granted on 2026-03-03. The grant was recorded at a stated price of $0.00 per share as a stock award, bringing his directly held Amgen shares to 87,877.
The direct holdings figure includes 624 Dividend Equivalents credited under Amgen’s 2009 Equity Incentive Plan, which pay out in common stock as related RSUs vest, with cash paid for any remaining fractional share amount. Separately, Santos has indirect holdings representing 903.8036 shares through the company’s 401(k) plan stock fund.
REESE DAVID M reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. executive David M. Reese, EVP & Chief Technology Officer, reported an equity award of 12,063 shares of common stock on March 3, 2026. The award was recorded at $0.00 per share, reflecting a grant rather than an open‑market purchase.
After this grant, Reese directly owned 47,650 Amgen common shares. This total includes 667 Dividend Equivalents (DEs) credited under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, which pay out in shares according to the vesting schedule.